The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries.  GHIF supports late-stage innovations for public health challenges such as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings.  GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.

As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years.  Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries.  High-volume / low-margin products, such as essential vaccines, are also of significant interest.

GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project.  Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.